Carisma Therapeutics has increased its series B round to $59m thanks to an extension backed by IP Group, Penn Medicine and 4Bio Capital.

Penn Medicine contributed to a $12m extension for the cancer immunotherapy developer's series B round, which already inlcuded Livzon, Merck & Co and AbbVie.

RTW Investments has a series C for the UT Southwestern and Gladstone Institutes spinout, which will progress its lead asset into the clinic.

Sutter Health, Novo, Sentara and Health Care Service Corporation are set to exit the virtual healthcare provider in an acquisition of undisclosed size.

The pension fund will pay an undisclosed sum for a 2% stake in API Holdings, the owner of online drugstore PharmEasy backed by Ascent Health and Medi Assist.

Satt Paris-Saclay portfolio company EG 427 has collected $14m in its first funding round.

AstraZeneca likely received over $1bn from selling its shares, having invested $140m in the publicly listed covid-19 vaccine developer in 2015.

Returning corporate investors Takeda Ventures and MRL Ventures Fund helped the cancer immunotherapy developer take its total funding to over $225m.

GC and its GC LabCell subsidiary both contributed to a round that will help advance the cancer immunotherapy developer's NK cell drug pipeline.

The KingMed Diagnostics and WuXi AppTec-backed cancer diagnosis technology developer intends to use the series C funding to bring its products to market.